Cynata Therapeutics Limited (CYP:ASX)

52.5¢

right-arrow Created with Sketch. 0 (0%)
MCAP $75.22M
Last trade 16.10pm 27/09/2021 20mins delayed

Latest Announcements

21/09/2021CYPCynata Therapeutics Limited
15/09/2021 Price SensitivePSCYPCynata Therapeutics Limited
31/08/2021 Price SensitivePSCYPCynata Therapeutics Limited
30/08/2021CYPCynata Therapeutics Limited
161
MCap
30/08/2021 Price SensitivePSCYPCynata Therapeutics Limited
26/08/2021 Price SensitivePSCYPCynata Therapeutics Limited
28/07/2021 Price SensitivePSCYPCynata Therapeutics Limited
26/07/2021CYPCynata Therapeutics Limited

Company Overview

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The Company's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.

CYP in the news

Cynata Therapeutics (CYP) receives ethics approval to begin a clinical trial of…
Cynata Therapeutics (CYP) appoints clinical research organisation Datapharm Australia to assist with…
Biotechnology company Cynata Therapeutics (CYP) has signed a worldwide exclusive licence agreement…
Cynata Therapeutics (CYP) has received ethics committee approval to expand the recruitment…

Search Previous Announcements